Dyadic International, Inc. Aktie News

Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Mark Emalfarb - President & CEO Ping Rawson - CFO Joseph Hazelton - COO Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, good evening, and welcome to Dyadic International's Q1 2024 Conference Call. Currently, all participants are in a liste...

Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are...

JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and...

JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will ...

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial...

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that Michael ...

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health a...